Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.

Mercier AE, Ribeiro E, Korobelnik JF, Delyfer MN, Rougier MB.

Ocul Immunol Inflamm. 2018;26(3):477-484. doi: 10.1080/09273948.2016.1236968. Epub 2016 Oct 24.

PMID:
27775458
2.

Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.

Schaap-Fogler M, Amer R, Friling R, Priel E, Kramer M.

Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):633-40. doi: 10.1007/s00417-013-2552-8. Epub 2013 Dec 24.

PMID:
24366669
3.

Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.

Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, Mesquida M, Adan AM, Herreras JM, Aparicio Á, Peiteado-Lopez D, Cordero-Coma M, García Serrano JL, Ortego-Centeno N, Maíz O, Blanco A, Sánchez-Bursón J, González-Suárez S, Fonollosa A, Santos-Gómez M, González-Vela C, Loricera J, Pina T, González-Gay MA.

Semin Arthritis Rheum. 2015 Dec;45(3):361-8. doi: 10.1016/j.semarthrit.2015.05.010. Epub 2015 May 21.

PMID:
26092330
4.

The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.

Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R, Neumann R, Kramer M.

Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):801-808. doi: 10.1007/s00417-018-3928-6. Epub 2018 Feb 18.

PMID:
29455252
5.

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF.

Ophthalmology. 2012 Aug;119(8):1575-81. doi: 10.1016/j.ophtha.2012.02.018. Epub 2012 Apr 21.

PMID:
22525047
6.

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.

Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, Bienvenu B, Abad S, Rigolet A, Deroux A, Sene D, Perlat A, Marie I, Feurer E, Hachulla E, Fain O, Clavel G, Riviere S, Bouche PA, Gueudry J, Pugnet G, Le Hoang P, Resche Rigon M, Cacoub P, Bodaghi B, Saadoun D; French Uveitis Network.

Arthritis Rheumatol. 2016 Jun;68(6):1522-30. doi: 10.1002/art.39667.

7.

intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.

Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF.

Retina. 2011 Feb;31(2):298-303. doi: 10.1097/IAE.0b013e3181eac7a6.

PMID:
21099452
8.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
9.

Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.

Llorenç V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maíz O, Blanco A, de Dios-Jiménez de Aberásturi JR, Adán A.

Ocul Immunol Inflamm. 2016;24(2):167-72. doi: 10.3109/09273948.2014.967779. Epub 2014 Oct 17.

PMID:
25325834
10.

Anti-TNF-alpha therapy for sight threatening uveitis.

Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM.

Br J Ophthalmol. 2005 May;89(5):533-6.

11.

Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.

Borrás-Blasco J, Casterá DE, Cortes X, Abad FJ, Rosique-Robles JD, Mallench LG.

Int J Clin Pharmacol Ther. 2015 May;53(5):377-90. doi: 10.5414/CP202171. Review.

PMID:
25345430
12.

Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.

Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, Pasadhika S, Lee ST, de Saint Sardos A, Butler NJ, Tessler HH, Smith JR, Rosenbaum JT.

Br J Ophthalmol. 2013 Apr;97(4):481-6. doi: 10.1136/bjophthalmol-2012-302292. Epub 2013 Feb 2.

PMID:
23376607
13.

Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L.

Clin Rheumatol. 2017 Jan;36(1):183-189. doi: 10.1007/s10067-016-3480-x. Epub 2016 Nov 16.

PMID:
27853889
14.

Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.

Petropoulos IK, Vaudaux JD, Guex-Crosier Y.

Klin Monbl Augenheilkd. 2008 May;225(5):457-61. doi: 10.1055/s-2008-1027361.

PMID:
18454398
15.

Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.

Lian F, Zhou J, Wei C, Wang Y, Xu H, Liang L, Yang X.

Clin Rheumatol. 2015 Nov;34(11):1913-20. doi: 10.1007/s10067-015-2989-8. Epub 2015 Jun 13.

PMID:
26070537
16.

A three-centre experience with adalimumab for the treatment of non-infectious uveitis.

Dobner BC, Max R, Becker MD, Heinz C, Veltrup I, Heiligenhaus A, Barisani-Asenbauer T, Mackensen F.

Br J Ophthalmol. 2013 Feb;97(2):134-8. doi: 10.1136/bjophthalmol-2011-301401. Epub 2012 Dec 4.

PMID:
23212204
17.

Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy.

Ilhan N, Ustun N, Tuzcu EA, Coskun M, Yagiz AE, Ilhan O, Parlakfikirer N.

Cutan Ocul Toxicol. 2015;34(3):222-6. doi: 10.3109/15569527.2014.956178. Epub 2014 Nov 3.

PMID:
25363064
18.

Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.

Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B, Modesto C, Díaz-Cordovés G, Palmou-Fontana N, Loricera J, González-Vela MC, Demetrio-Pablo R, Hernández JL, González-Gay MA, Blanco R.

Arthritis Rheumatol. 2017 Mar;69(3):668-675. doi: 10.1002/art.39940.

19.

Anti-tumor necrosis factor-α therapy in uveitis.

Cordero-Coma M, Sobrin L.

Surv Ophthalmol. 2015 Nov-Dec;60(6):575-89. doi: 10.1016/j.survophthal.2015.06.004. Epub 2015 Jul 9. Review.

PMID:
26164735
20.

Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Galor A, Perez VL, Hammel JP, Lowder CY.

Ophthalmology. 2006 Dec;113(12):2317-23. Epub 2006 Sep 25.

PMID:
16996615

Supplemental Content

Support Center